Showing 431-440 of 9358 results for "".
- Celebrate National Botox Day on November 20, 2019https://practicaldermatology.com/news/celebrate-national-botox-day-on-november-20th-2019/2460218/Mark your calendars: November 20, 2019 will be the first-ever National Botox Cosmetic Day. Why Nov. 20? It is the busiest day on record for booking Botox cosmetic treatments in the US. And to commemorate it, Allergan is offering an exclusive deal for one day only where patients can “buy one, get …
- Allergan Adds Coolsculpting, Other Bells and Whistles to Brilliant Distinctions® Patient Loyalty Programhttps://practicaldermatology.com/news/allergan-adds-coolsculpting-other-bells-and-whistles-to-brilliant-distinctions-patient-loyalty-program/2458056/Allergan is launching the next generation of its U.S.-based Brilliant Distinctions® program. The new offering incorporates digital innovation to enhance the consumer experience and drive increased member engagement. In addition, Brilliant Distinctions® is also expanding to include CoolSculpting® i…
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind trials (EV001 and EV002), the composit…
- More Than 1,000 Patients Join Corrona Psoriasis Registryhttps://practicaldermatology.com/news/more-than-1000-patients-join-corrona-psoriasis-registry/2458631/The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, now includes more than 1,000 patients from 100 sites. Dermatologists assess registry patients every six months during routine visits and fill out a comprehensive questionnaire. P…
- ZELTIQ® Taps Todd Zavodnick as New President, Internationalhttps://practicaldermatology.com/news/zeltiq-taps-todd-zavodnick-as-new-president-international/2458708/Todd Zavodnick is the new President, International of ZELTIQ®. Mr. Zavodnick will be responsible for driving the company’s international growth and expansion. He recently served as President and General Manager for Galderma Laboratories, North America. Prior to that, Mr. Zavodnick led commercia…
- AAD Releases New App to Aid Patients with Chronic Hiveshttps://practicaldermatology.com/news/aad-releases-new-app-to-aid-patients-with-chronic-hives/2458798/The American Academy of Dermatology (AAD) released its Chronic Hives Patient App, which offers tools and resources for chronic hives management. The free mobile app, developed with a grant from Novartis Pharmaceuticals Corp., can help patients learn more about their condition, find a doctor, track …
- Foamix Pharmaceuticals Will Host Key Opinion Leader Meeting and Webcast on November 4th in New York Cityhttps://practicaldermatology.com/news/20141029-foamix_pharmaceuticals_will_host_key_opinionleader_meeting_and_webcast_on_november_4th_in_new_york_city/2459077/Foamix Pharmaceuticals Ltd. will host a Key Opinion Leader breakfast on Tuesday, November 4, 2014 from 8:00am-9:30am Eastern Time in New York City. The meeting will feature key opinion leader Mark Lebwohl, MD, who leads a renowned dermatology program in the U.S., as the Sol and Clara Kest Profess…
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experiencing more se…
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeutic inertia in the treatment of moderate-to-severe atopic dermatitis (AD), even with the advent of newer, advanced systemic therapies. Over a 12-m…
- FDA Approves BMS’ Opdivo (Nivolumab) for Adjuvant Treatment of Eligible Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/fda-approves-bms-opdivo-nivolumab-for-adjuvant-treatment-of-eligible-patients-with-completely-resected-stage-iib-or-iic-melanoma/2462074/The U.S. Food and Drug Administration (FDA) has given its nod to Opdivo (nivolumab) for the adjuvant treatment of eligible adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma. This approval was based on the Phase 3 CheckMate -76K trial, which compare…